Combretastatin-chalcone hybrids: synthesis and cytotoxicity

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Chalcones and combretastatins are known for their biological activities, including anti-cancer properties.
• Hybrid molecules can offer synergistic or novel therapeutic effects.
• Developing new anti-cancer agents is crucial for treating diverse malignancies.

Purpose of the Study:

• To synthesize and characterize a novel series of hybrid compounds merging chalcone and combretastatin scaffolds.
• To evaluate the in vitro cytotoxic activity of these compounds against a panel of cancer cell lines.
• To establish structure-activity relationships (SAR) guiding the design of more potent anti-cancer agents.

Main Methods:

• Synthesis of all-trans-1-aryl-4-aryl-5-aryl-2,4-pentanediene-1-one derivatives.
• In vitro cytotoxicity assays using B16 (murine melanoma), HCT116 (colon cancer), A431 (human epidermoid carcinoma), and human umbilical venous endothelial cells (HUVEC).
• Structure-activity relationship analysis to identify key structural features responsible for activity.

Main Results:

• A series of hybrid compounds were successfully synthesized.
• Cytotoxicity was observed across tested cancer cell lines, with varying potency.
• The presence of a 2,5-dihydroxyphenyl moiety at position 1 of the pentadienone core was found to be essential for significant cytotoxicity.
• Compound 3a, all-trans-1-(2,5-Dihydroxyphenyl)-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-2,4-pentanediene-1-one, exhibited the highest potency within the series.

Conclusions:

• The synthesized chalcone-combretastatin hybrids represent a promising class of anti-cancer agents.
• The 2,5-dihydroxyphenyl substitution is a critical determinant for potent anti-cancer activity in this molecular framework.
• Compound 3a warrants further investigation as a potential lead candidate for cancer therapy.